WO2020040474A1 - Procédé pour préparer une préparation contenant une couche à libération immédiate de sitagliptine, préparation préparée par le procédé de préparation, procédé permettant de déposer la couche à libération immédiate de sitagliptine, et composition pour former par dépôt la couche à libération immédiate de sitagliptine - Google Patents

Procédé pour préparer une préparation contenant une couche à libération immédiate de sitagliptine, préparation préparée par le procédé de préparation, procédé permettant de déposer la couche à libération immédiate de sitagliptine, et composition pour former par dépôt la couche à libération immédiate de sitagliptine Download PDF

Info

Publication number
WO2020040474A1
WO2020040474A1 PCT/KR2019/010317 KR2019010317W WO2020040474A1 WO 2020040474 A1 WO2020040474 A1 WO 2020040474A1 KR 2019010317 W KR2019010317 W KR 2019010317W WO 2020040474 A1 WO2020040474 A1 WO 2020040474A1
Authority
WO
WIPO (PCT)
Prior art keywords
cytagliptin
coating
release layer
immediate release
preparation
Prior art date
Application number
PCT/KR2019/010317
Other languages
English (en)
Korean (ko)
Inventor
양재권
추성남
장지선
김서현
현우석
강민권
김가현
송영경
김예슬
Original Assignee
대화제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대화제약 주식회사 filed Critical 대화제약 주식회사
Publication of WO2020040474A1 publication Critical patent/WO2020040474A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Definitions

  • the present invention provides a method for preparing a formulation comprising a cytagliptin immediate release layer,
  • It relates to a formulation prepared for, a method for coating cytagliptin immediate release layer, and a composition for coating a cytagliptin immediate release layer.
  • Sitagliptin is a type 2 diabetes treatment that is a dipeptidyl peptidase-4 (DPP-4) inhibitor.
  • Citagliptin is marketed under the product names Januvia, Janumet, and Janumet X-R (MSD) in Korea, and the active ingredient is in the form of citagliptin phosphate monohydrate (dipeptidyl peptidase-IV inhibitor Phosphate, Korean Patent No. 10-1016569).
  • xanumetxal is composed of a sustained release layer of metformin and a cytagliptin immediate release layer, and in connection with the preparation method of the cytagliptin immediate release layer, an international patent pharmaceutical composition of a combination of Metformin and a Dipetidyl Peptidase-IV Inhibitor (WO 2009 -099734 A1) provides a rapid release layer of cytagliptin, but since this technique uses a low volatility solvent, there is a big problem that the rapid release layer of cytagliptin can be completed only after a long coating process.
  • the present inventors have studied to develop a method for preparing a formulation including a cytagliptin immediate release layer having a shorter coating time, and thus, the present invention has been completed to reduce the coating time without generating decomposition products.
  • An object of the present invention comprises (a) dissolving cytagliptin or a pharmaceutically acceptable salt thereof in a highly volatile solvent to prepare a coating solution, and (b) coating the sustained release layer with the coating solution. It is to provide a method for producing a formulation comprising a liptin immediate release layer.
  • Another object of the present invention comprises the steps of preparing a coating solution by dissolving cytagliptin or a pharmaceutically acceptable salt thereof in a high volatility solvent, and (b) coating the sustained release layer with the coating solution. It is to provide a method for coating the immediate release layer of gliptin.
  • Still another object of the present invention is to provide a composition for cytagliptin immediate release layer containing cytagliptin hydrochloride and a high volatility solvent.
  • Still another object of the present invention is to provide a preparation prepared by the preparation method of the preparation.
  • the method for preparing a formulation comprising a cytagliptin immediate release layer, a method for coating a cytagliptin immediate release layer, and a composition for coating a cytagliptin immediate release layer may reduce coating time and generate a flexible material by using a high volatility solvent. It is effective to avoid.
  • 1 is a diagram showing the solubility of cytagliptin phosphate hydrate in water and ethanol.
  • FIG. 2 is a diagram showing the solubility of cytagliptin hydrochloride hydrate in water and ethanol.
  • Figure 3 is a view showing the result of measuring the degree of generation of the flexible material of (a) cytagliptin phosphate hydrate and (b) cytagliptin hydrochloride hydrate exposed to room temperature or 60 °C for 48 hours.
  • Figure 4 shows one specific form of a formulation comprising a cytagliptin immediate release layer.
  • the present invention comprises the steps of (a) dissolving cytagliptin or a pharmaceutically acceptable salt thereof in a high-volatile solvent to prepare a coating solution and (b) to form a sustained release layer with the coating solution It provides a method for preparing a formulation comprising a cytagliptin immediate release layer comprising the step of coating.
  • cytagliptin of the present invention is an orally active dipeptidyl peptidase-4 (DPP-4) inhibitor known to improve sugar control in patients with type 2 diabetes by slowing the inactivation of the incretin hormone.
  • the chemical structure of cytagliptin may be represented by the following Chemical Formula 1, and the chemical name of cytagliptin is (R) -3-amino-1- (3- (trifluoromethyl) -5,6-dihydro- [ 1,2,4] triazolo [4,3-a] pyrazin-7 (8H) -yl) -4- (2,4,5-trifluorophenyl) butan-1-one.
  • Cytagliptin is also included in the present invention without limitation, in which some functional groups are modified or protected with protecting groups as long as the dipeptidyl-peptidase-4 inhibitory effect is maintained.
  • cytagliptin is a concept including all of its pharmaceutically acceptable salts, hydrates, solvates, isomers, derivatives, and the like within the range having the same efficacy. Cytagliptin of the present invention may be obtained by using chemically synthesized or commercially available materials.
  • the pharmaceutically acceptable salt of cytagliptin may be prepared from an inorganic base, an organic base, an inorganic acid, or an organic acid, but is not limited thereto.
  • Pharmaceutically acceptable salts of cytagliptin derived from inorganic bases include, but are not limited to, aluminum, ammonium, calcium, copper, ferrous iron, ferric iron, lithium, magnesium, potassium, sodium, zinc and the like.
  • Pharmaceutically acceptable salts of cytagliptin derived from organic bases include primary amines, secondary amines, tertiary amines, substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically arginine, Betaine, caffeine, choline, NN-dibenzylethylene diamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, histidine, lysine, piperazine, Piperidine, polyamine resin, procaine, purine, triethylamine, trimethylamine, and the like, but are not limited thereto.
  • cytagliptin derived from inorganic or organic acids include, but are not limited to, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, bromic acid, Hydrochloric acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, nitric acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, and the like.
  • Cytagliptin or a pharmaceutically acceptable salt of cytagliptin may be in the form of a hydrate, but is not limited thereto.
  • the pharmaceutically acceptable salt of cytagliptin may be at least one selected from the group consisting of cytagliptin hydrochloride, cytagliptin phosphate, cytagliptin sulfate, cytagliptin acetate, and cytagliptin malate salt.
  • the pharmaceutically acceptable salt of cytagliptin is cytagliptin hydrochloride.
  • compositions of cytagliptin may have different solubility and / or stability even in the same solvent depending on the kind thereof, and the degree of generation of the flexible substance may be different when the cytagliptin immediate release layer is coated using the same. have.
  • the cytagliptin phosphate has low solubility in a high volatility solvent such as ethanol (FIG. 1), and the cytagliptin immediate release layer may be coated using the cytagliptin phosphate in the solvent.
  • a high volatility solvent such as ethanol
  • cytagliptin hydrochloride has a relatively high solubility in a high volatility solvent such as ethanol (FIG.
  • the pharmaceutically acceptable salt of cytagliptin may be included in an amount of 0.6 to 60 parts by weight based on 100 parts by weight of the solvent.
  • the solvent may be included in an amount of 0.6 to 40, more specifically 0.6 to 20, more specifically 0.6 to 10, 1 to 10, 2 to 10, 3 to 9, or 4 to 8 parts by weight.
  • the coating solution of the present invention is a fluid for coating the sustained release layer of the bilayer tablet, and includes the cytagliptin or a pharmaceutically acceptable salt thereof, and may form an immediate release layer simultaneously with the coating of the sustained release layer.
  • the present invention may be in the form of dissolving cytagliptin or a pharmaceutically acceptable salt thereof in the high volatile solvent.
  • the coating liquid may further include one or more selected from the group consisting of hypromellose, polyvinyl alcohol, hydroxypropyl cellulose, povidone, polyethylene glycol, kaolin, propyl gallate, However, any ingredient that does not affect the pharmacological activity and is beneficial to the coating performance may be included without limitation.
  • the high volatile solvent means a high volatility solvent, it is preferable that the biotoxicity is low.
  • the high volatile solvent contributes to shortening the coating time, and enables the rapid release of the immediate release layer including the biologically active ingredient having high solubility in the solvent while having a high content of the active ingredient.
  • the high volatile solvent may include one or more selected from the group consisting of anisole, ethanol, acetone, butyl methyl ether, methyl ethyl ketone, methyl isobutyl ketone, pentane, heptane.
  • the high volatile solvent may include ethanol at 5%, 10%, 15%, or 20% or more of the total solvent weight.
  • the high volatile solvent may be a mixed solvent of ethanol and water or ethanol. Due to the high volatility of the solvent, the time for coating the sustained release layer with the cytagliptin immediate release layer can be shortened. Specifically, the coating time was 8 hours when using water as a solvent was shortened to 2 hours when using 80% ethanol.
  • the dissolution means that the solute is diffused into the solvent and mixed, and the dissolution in the present invention includes not only the solute being uniformly mixed in the solvent but also the solute is unevenly mixed in the solvent to form a suspension, a colloid, and the like.
  • the coating means coating all or part of the outer surface of the sustained release layer with a thin film using the coating liquid.
  • the method of coating is not limited, and may be performed by one or more methods selected from the group consisting of a fan coating method and a fluidized bed coating method.
  • the coating may be performed at or above room temperature, specifically, 50 to 90 ° C., 52 to 88 ° C., 56 to 84 ° C., 58 to 82 ° C., or 60 to 80 ° C., but is not limited thereto.
  • the formulations of the present invention comprise a sustained release layer comprising a biologically active substance, filler, disintegrant, diluent, additive, glidant, excipient, etc. and cytagliptin or a pharmaceutically acceptable salt, filler, disintegrant, diluent, additive, It may be a two-layered tablet or a multilayered tablet including an immediate release layer including a lubricant, an excipient, and the like, but is not limited thereto.
  • the formulation of the present invention may further include a pharmaceutically acceptable carrier.
  • Examples of the pharmaceutically acceptable carrier include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, undetermined. Vaginal cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used. In addition, excipients, fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers and preservatives may be further included.
  • Disintegrants are used to absorb moisture and promote disintegration of the formulation to enhance cytagliptin or salt dissolution thereof.
  • Non-limiting examples of disintegrants used in the immediate release layer and the sustained release layer in the present invention are each independently croscamellose sodium, sodium starch glycolate, microcrystalline cellulose, Crospovidone (cross-linked povidone) and other commercially available polyvinylpyrrolidone (PVP, Povidone), low-substituted hydroxypropylcellulose (low substituted), alginic acid, powdered cellulose Starch, sodium alginate, and mixtures thereof.
  • Disintegrant may use 2 to 15% by weight, more specifically 5 to 10% by weight based on the total weight of the formulation, but is not limited thereto.
  • Non-limiting examples of excipients used in the immediate release layer and the sustained release layer in the present invention may each independently be lactose, mannitol, glucose, sorbitol, dextrin, sucrose, or mixtures thereof.
  • the present invention can use a binder that serves to increase the binding strength of the formulation to the immediate release layer and the sustained release layer.
  • binders that can be used include polyvinylpyrrolidone (common name: povidone), but may be added in 3 to 10% by weight of the total weight of the formulation, but is not limited thereto.
  • Non-limiting examples of glidants usable in the immediate release layer and the sustained release layer in the present invention may each independently be light silicic anhydride, silicon dioxide, talc, stearic acid, magnesium stearate or mixtures thereof. Glidants facilitate the compression and release of tablets, and may add 0.5 to 5% by weight relative to the weight of the formulation, but is not limited thereto.
  • the sustained release layer means a slower release of biologically active material than the immediate release layer.
  • the sustained release layer may be spherical or plate-like.
  • the biologically active substance included in the sustained release layer may be metformin or a pharmaceutically acceptable salt thereof, but is not limited thereto.
  • compositions of metformin include inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trichloroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, Acid addition salts formed by organic carbon acids such as maleic acid, salicylic acid and the like, sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.
  • inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trichloroacetic acid, gluconic acid, benzoic acid,
  • salts of metformin include metal salts or alkaline earth metal salts formed by lithium, sodium, potassium, calcium, magnesium and the like, amino acid salts such as lysine, arginine, guanidine, dicyclohexylamine, N-methyl-D Organic salts such as -glucamine, tris (hydroxymethyl) methylamine, diethanolamine, choline and triethylamine and the like.
  • the immediate release layer is a layer formed by coating the sustained release layer with the coating solution, and refers to a layer that releases the biologically active substance in vivo enough to achieve a desired effect in a patient within a limited time.
  • the biologically active substance included in the immediate release layer is cytagliptin or a pharmaceutically acceptable salt thereof.
  • the immediate release layer may be spherical or plate-shaped, but is not limited thereto.
  • the immediate release layer and the sustained release layer of the present invention may be formed by tableting granules of a mixture comprising a biologically active substance, the granules comprising dry granules or wet granules, and may be prepared by any method known in the art. Can be.
  • the formulation of the present invention has a total weight of 2000 mg or less, specifically 500 mg to 2000 mg, 600 to 2000 mg, 700 to 2000 mg, 800 to 2000 mg, 900 to 2000 mg, 1000 mg to 2000 mg, 1100 to 2000 mg , 1400 to 2000 mg, or 1500 to 2000 mg, but the total weight of the formulation may be appropriately selected and implemented by those skilled in the art to satisfy the required efficacy.
  • Cytagliptin or a salt thereof, which is a biologically active substance may be included in an amount of 2 to 10 wt%, specifically 3 to 7 wt%, based on the weight of the preparation, but is not limited thereto.
  • the formulations may be prepared in various formulations using the pharmaceutically acceptable carrier, and may be tablets, powders, granules or capsules such as uncoated tablets, film coated tablets, bilayer tablets, multi-layer tablets or nucleated tablets, and the like.
  • the preparation method of the formulation of the present invention may be to shorten the coating time without generating decomposition products.
  • the formulation can be prepared with high coating performance by coating the sustained release layer with a coating solution in which cytagliptin hydrochloride is dissolved in a high volatile solvent (eg, ethanol).
  • a high volatile solvent eg, ethanol
  • the formulation prepared by the method of the present invention is expected to have excellent industrial value by including cytagliptin hydrochloride as an immediate release layer and exhibiting high productivity while having the same efficacy as a conventional known cytagliptin formulation.
  • the present invention comprises the steps of (a) dissolving cytagliptin or a pharmaceutically acceptable salt thereof in a high volatile solvent to prepare a coating solution, and (b) coating the sustained release layer with the coating solution.
  • a coating solution to prepare a coating solution
  • a coating solution to prepare a coating solution
  • a coating solution to prepare a coating solution
  • a coating solution to prepare a coating solution
  • a coating solution to prepare a coating solution
  • coating method of the present invention is expected to increase the quality and productivity of the formulation including the cytagliptin immediate release layer coating because it shortens the coating time without generating decomposition products.
  • the present invention provides a composition for coating a cytagliptin immediate release layer comprising a cytagliptin hydrochloride and a high volatile solvent.
  • the cytagliptin hydrochloride may be present in a dissolved state in a solvent.
  • the coating composition including cytagliptin hydrochloride and a high volatile solvent shortens the coating time and generates little decomposition products. From this, the inventors confirmed that when the composition for coating containing cytagliptin hydrochloride and a high volatile solvent is used, coating time of the preparation is shortened and the formation of a flexible material is inhibited, thereby improving coating performance.
  • the present invention provides a method of preparing a coating solution by dissolving cytagliptin or a pharmaceutically acceptable salt thereof in a high volatile solvent, and (b) coating the sustained release layer with the coating solution.
  • a formulation prepared by a manufacturing method comprising.
  • the formulation may be one having a dissolution rate of more than 80% of cytagliptin within 60 minutes when the dissolution test in purified water according to the Korean Pharmacopoeia dissolution test method 2 (paddle method), rotation speed 100 rpm.
  • Such formulations contain low amounts of softeners and are of good quality.
  • Such a method for preparing a formulation comprising a cytagliptin immediate release layer, a method for coating a cytagliptin immediate release layer, and a composition for coating a cytagliptin immediate release layer can shorten a coating time without generating a flexible material. Has a beneficial effect.
  • the present inventors analyzed solubility in water and ethanol of cytagliptin phosphate and cytagliptin hydrochloride to analyze the difference in solubility according to the type of cytagliptin salt.
  • Citagliptin Phosphate Hydrates According to the Solvent Composition number One 2 3 4 5 Citagliptin Phosphate Heptahydrate 0.6 g 0.6 g 0.6 g 0.6 g 0.6 g Purified water 100% 80% 60% 20% - ethanol - 20% 40% 80% 100% Solubility Almost clear solution Translucent suspension Opaque suspension Opaque suspension Opaque suspension
  • Citagliptin Hydrochloride Hydrate According to Solvent Composition number 6 7 8 9 10 Citagliptin Hydrochloride Hydrate 0.6 g 0.6 g 0.6 g 0.6 g 0.6 g Purified water 100% 80% 60% 20% - ethanol - 20% 40% 80% 100% Solubility Clear solution Clear solution Clear solution Clear solution Opaque suspension
  • the coating time, content, and degree of formation of the flexible material according to the cytagliptin salt and the type of the solvent were analyzed as follows.
  • Buffer Potassium dihydrogenphosphate 1.36 g was precisely weighed and placed in 1000 mL water, adjusted to pH 6.8 using dilute potassium hydroxide solution, filtered and degassed.
  • Mobile phase B Acetonitrile and water were mixed at a ratio of 85:15.
  • cytagliptin 30 mg was collected, put into a 100 mL flask, and diluted with a diluent to completely dissolve it, and then used as a sample solution after marking.
  • Buffer Potassium dihydrogenphosphate 1.36 g was precisely weighed and placed in 1000 mL water, adjusted to pH 6.8 using dilute potassium hydroxide solution, filtered and degassed.
  • Mobile phase B Acetonitrile and water were mixed at a ratio of 85:15.
  • the present inventors coated the metformin sustained release layer with cytagliptin hydrochloride hydrate in place of cytagliptin phosphate hydrate according to the prior art (WO 2009-099734 A1). At this time, the amount of cytagliptin hydrochloride was adjusted so that 100 mg per tablet of cytagliptin was added.
  • citaliptin hydrochloride hydrate (Dr Reddy), 75 g of hypromellose 2910 (6 cp), 15 g of polyethylene glycol 3350, 30 g of kaolin, 1.274 g of propyl gallate, and 2 g of Lake No. 2 in ethanol 1408 g and purified water 352 g (80% ethanol) was added and stirred for 4 hours to prepare a coating solution.
  • 1.2 kg of tablets containing metformin 1000 mg were put in a King Sejong coating machine 30SFC and coated with the prepared coating solution at an air supply temperature of 60 to 80 ° C., and then the coating time was measured. The contents and the degree of generation of the flexible substance were evaluated.
  • the coating time measured was within 2 hours, the content was 99.2%, and no degradation product was observed.
  • the present inventors prepared a coating solution having a low content of ethanol in Example 3-1 to compare the coating performance. Specifically, metformin was coated according to the prior art (WO 2009-099734 A1). At this time, the amount of the cytagliptin salt triad was adjusted so that 100 mg per tablet may be added.
  • citaliptin hydrochloride hydrate (Dr Reddy), 75 g of hypromellose 2910 (6 cp), 15 g of polyethylene glycol 3350, 30 g of kaolin, 1.274 g of propyl gallate, and 2 g of Lake No. 2 in ethanol 352 g and 1408 g (20% ethanol) of purified water were added and stirred for 4 hours to prepare a coating solution.
  • 1.2 kg of tablets containing metformin 1000 mg were put in a King Sejong coating machine 30SFC and coated with the prepared coating solution at an air supply temperature of 60 to 80 ° C., and then the coating time was measured. The contents and the degree of generation of the flexible substance were evaluated.
  • the measured coating time was within 5 hours, the estimated content was 100.6%, and no degradation product was observed.
  • the present inventors prepared a coating solution containing cytagliptin phosphate instead of cytagliptin hydrochloride for comparison with cytagliptin hydrochloride, and coated metformin according to the prior art (WO 2009-099734 A1) with the prepared coating liquid.
  • the coating time measured was 8 hours, and the estimated content was 98.4%. In addition, no degradation products were observed.
  • the present inventors prepared a coating solution using a solvent having a high ethanol content, unlike Example 3-3, and tried to compare the coating performance. Metformin was coated according to the prior art (WO 2009-099734 A1) with the prepared coating liquid.
  • cytagliptin phosphate hydrate Biochem
  • 75 g of hypromellose 2910 (6 cp)
  • 15 g of polyethylene glycol 3350, 30 g of kaolin, 1.274 g of propyl gallate, and 2 lake of Blue No. 80 1760 g of% ethanol was added and stirred for 4 hours to prepare a coating solution.
  • 1.2 kg of tablets containing metformin 1000 mg were placed in a Sejong coating machine 30SFC, coated with the prepared coating solution at an air supply temperature of 60 to 80 ° C., and then the coating time was measured, and the content was evaluated by the content analysis method described above.
  • the coating time measured was about 2 hours, and the estimated content was 74.7%.
  • the reason for this low content is that the physical dissipation occurred when spraying the coating liquid due to poor solubility of cytagliptin phosphate hydrate in ethanol.
  • the coating liquid prepared to contain cytagliptin phosphate was controlled at room temperature and air supply temperature of 60 ° C by adjusting the temperature of the preparation tank. After exposure for 48 hours, the degradation products of the coating solution were evaluated. At this time, the cytagliptin hydrochloride was also compared.
  • cytagliptin hydrochloride for the formulation including the cytagliptin immediate release layer and to include a high volatile solvent such as ethanol in the coating solution.
  • a high volatile solvent such as ethanol
  • the present inventors have determined the dissolution rate of citagliptin of ZanmethexAlser tablet 100 mg / 1000 mg (manufacture number: M037400) and the citagliptin dissolution rate of a formulation prepared by coating the sustained release layer of metformin with citagliptin hydrochloride in Example 1 Comparison was made.
  • the dissolution rate of citaliptin in the formulation of Xanmet X RDS and the formulation of Example 1 was measured by dissolution test in purified water according to the Korean Pharmacopoeia Dissolution Test Method 2 (paddle method), rotational speed 100rpm.
  • Example 1 shows a dissolution rate of more than 80% within 30 minutes, similar to the Zanumet X R.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un procédé pour préparer une préparation contenant une couche à libération immédiate de sitagliptine, une préparation préparée par le procédé de préparation, un procédé permettant de déposer la couche à libération immédiate de sitagliptine, et une composition pour former par dépôt la couche à libération immédiate de sitagliptine, le procédé de préparation comprenant les étapes consistant : (a) à préparer une solution de dépôt par dissolution de sitagliptine ou d'un sel pharmaceutiquement acceptable de celle-ci dans un solvant hautement volatil ; et (b) à former par dépôt une couche à libération prolongée à l'aide de la solution de dépôt.
PCT/KR2019/010317 2018-08-21 2019-08-13 Procédé pour préparer une préparation contenant une couche à libération immédiate de sitagliptine, préparation préparée par le procédé de préparation, procédé permettant de déposer la couche à libération immédiate de sitagliptine, et composition pour former par dépôt la couche à libération immédiate de sitagliptine WO2020040474A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180097553A KR20200021774A (ko) 2018-08-21 2018-08-21 시타글립틴 속방층을 포함하는 제제의 제조방법, 상기 제조방법으로 제조된 제제, 시타글립틴 속방층 코팅 방법, 및 시타글립틴 속방층 코팅용 조성물
KR10-2018-0097553 2018-08-21

Publications (1)

Publication Number Publication Date
WO2020040474A1 true WO2020040474A1 (fr) 2020-02-27

Family

ID=69592520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/010317 WO2020040474A1 (fr) 2018-08-21 2019-08-13 Procédé pour préparer une préparation contenant une couche à libération immédiate de sitagliptine, préparation préparée par le procédé de préparation, procédé permettant de déposer la couche à libération immédiate de sitagliptine, et composition pour former par dépôt la couche à libération immédiate de sitagliptine

Country Status (2)

Country Link
KR (1) KR20200021774A (fr)
WO (1) WO2020040474A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114010612A (zh) * 2021-11-24 2022-02-08 上海普康药业有限公司 一种西格列汀二甲双胍双层缓释片及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220165346A (ko) 2021-06-08 2022-12-15 동아에스티 주식회사 에보글립틴의 안정성이 개선된 제제

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113000A1 (fr) * 2007-03-15 2008-09-18 Nectid, Inc. Combinaisons anti-diabétiques comprenant une composition de biguanide à libération lente et une composition d'inhibiteur de dipeptidyl peptidase iv à libération immédiate
WO2009070314A2 (fr) * 2007-11-26 2009-06-04 Teva Pharmaceutical Industries Ltd. Forme cristalline de sitagliptine
WO2009099734A1 (fr) * 2008-02-05 2009-08-13 Merck & Co., Inc. Compositions pharmaceutiques d'une association de metformine et d'un inhibiteur de la dipeptidyle peptidase-iv
KR20120083276A (ko) * 2009-10-09 2012-07-25 영진약품공업주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
KR20130010044A (ko) * 2011-07-14 2013-01-24 주식회사 바이오파마티스 콜린 알포세레이트 또는 이의 약학적으로 허용되는 염을 포함하는 서방형 약학 조성물 및 이의 제조방법
WO2015166472A1 (fr) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Compositions de metformine liquides à libération prolongée
KR20160111237A (ko) * 2015-03-16 2016-09-26 한미약품 주식회사 메트포르민 및 시타글립틴을 포함하는 경구용 복합제제

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113000A1 (fr) * 2007-03-15 2008-09-18 Nectid, Inc. Combinaisons anti-diabétiques comprenant une composition de biguanide à libération lente et une composition d'inhibiteur de dipeptidyl peptidase iv à libération immédiate
WO2009070314A2 (fr) * 2007-11-26 2009-06-04 Teva Pharmaceutical Industries Ltd. Forme cristalline de sitagliptine
WO2009099734A1 (fr) * 2008-02-05 2009-08-13 Merck & Co., Inc. Compositions pharmaceutiques d'une association de metformine et d'un inhibiteur de la dipeptidyle peptidase-iv
KR20120083276A (ko) * 2009-10-09 2012-07-25 영진약품공업주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
KR20130010044A (ko) * 2011-07-14 2013-01-24 주식회사 바이오파마티스 콜린 알포세레이트 또는 이의 약학적으로 허용되는 염을 포함하는 서방형 약학 조성물 및 이의 제조방법
WO2015166472A1 (fr) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Compositions de metformine liquides à libération prolongée
KR20160111237A (ko) * 2015-03-16 2016-09-26 한미약품 주식회사 메트포르민 및 시타글립틴을 포함하는 경구용 복합제제

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114010612A (zh) * 2021-11-24 2022-02-08 上海普康药业有限公司 一种西格列汀二甲双胍双层缓释片及其制备方法
CN114010612B (zh) * 2021-11-24 2022-06-28 上海普康药业有限公司 一种西格列汀二甲双胍双层缓释片及其制备方法

Also Published As

Publication number Publication date
KR20200021774A (ko) 2020-03-02

Similar Documents

Publication Publication Date Title
US20050027011A1 (en) Serotonin reuptake inhibitor formulations
WO2020040474A1 (fr) Procédé pour préparer une préparation contenant une couche à libération immédiate de sitagliptine, préparation préparée par le procédé de préparation, procédé permettant de déposer la couche à libération immédiate de sitagliptine, et composition pour former par dépôt la couche à libération immédiate de sitagliptine
WO2016105084A2 (fr) Composition pharmaceutique pour le traitement du diabète
WO2020040438A1 (fr) Préparation pharmaceutique ayant d'excellentes propriétés de dissolution, contenant de l'ésoméprazole et du bicarbonate de sodium
EP3089739A1 (fr) Préparation composite pour une administration orale comportant de l'ézétimibe et de la rosuvastatine
WO2018160043A1 (fr) Préparation, comprenant un complexe d'inclusion de varénicline ou d'un sel pharmaceutiquement acceptable de celle-ci, pour administration par voie orale
WO2019147094A1 (fr) Formulation pharmaceutique comprenant de l'ésoméprazole et du bicarbonate de sodium
WO2015115750A1 (fr) Composition pharmaceutique stable contenant de la solifénacine, et son procédé de préparation
WO2016036093A1 (fr) Film dispersible oral de tadalafil et son procédé de préparation
WO2016060365A1 (fr) Formulation de metformine à libération prolongée et procédé pour sa préparation
WO2020242132A1 (fr) Comprimé gastrorésistant contenant du fumarate de diméthyle
WO2019004770A9 (fr) Composition pour préparation solide à usage oral comprenant un inhibiteur de pompe à protons, préparation solide à usage oral la comprenant, et son procédé de préparation
WO2022103233A1 (fr) Formulation pharmaceutique composite comprenant du rabéprazole et un antiacide, et son procédé de préparation
WO2017082577A1 (fr) Préparation solide contenant de la solifénacine amorphe à usage oral et son procédé de préparation
WO2019221488A1 (fr) Formulation pharmaceutique comprenant de l'apixaban et son procédé de préparation
WO2015194923A1 (fr) Préparation pharmaceutique contenant de l'entécavir en tant que principe actif, et son procédé de préparation
WO2018124700A1 (fr) Nouvelle préparation contenant un dérivé de benzimidazole
WO2016159572A1 (fr) Formulation orale solide contenant de l'oseltamivir, et son procédé de préparation
WO2019013583A2 (fr) Préparation pharmaceutique et son procédé de préparation
WO2015102337A1 (fr) Composition pharmaceutique contenant de la clomipramine et son procédé de préparation
WO2020022824A1 (fr) Formulation pharmaceutique comprenant de l'edoxaban et son procédé de préparation
WO2022139223A1 (fr) Film à désintégration orale comprenant du naratriptan
WO2021002588A1 (fr) Composition pharmaceutique contenant de la tamsulosine ou un chlorhydrate de tamsulosine et procédé de préparation associé
WO2023022520A1 (fr) Composition de comprimé oral de ruxolitinib et son procédé de préparation
WO2013157840A1 (fr) Composition composite présentant une stabilité améliorée et contenant de l'amlodipine et du rozaltan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19850998

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19850998

Country of ref document: EP

Kind code of ref document: A1